Kennedy Capital Management LLC Grows Position in Health Catalyst, Inc. (NASDAQ:HCAT)

Kennedy Capital Management LLC increased its position in shares of Health Catalyst, Inc. (NASDAQ:HCAT) by 42.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,891,000 shares of the company’s stock after acquiring an additional 565,445 shares during the quarter. Kennedy Capital Management LLC owned approximately 3.11% of Health Catalyst worth $13,369,000 as of its most recent filing with the SEC.

Several other large investors have also recently added to or reduced their stakes in the business. Impax Asset Management Group plc boosted its holdings in Health Catalyst by 7.7% in the 4th quarter. Impax Asset Management Group plc now owns 2,750,000 shares of the company’s stock worth $19,442,000 after acquiring an additional 195,525 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Health Catalyst by 4.9% in the 3rd quarter. Geode Capital Management LLC now owns 1,443,036 shares of the company’s stock valued at $11,749,000 after buying an additional 66,896 shares during the period. State Street Corp lifted its holdings in Health Catalyst by 2.5% in the third quarter. State Street Corp now owns 1,163,754 shares of the company’s stock worth $9,473,000 after acquiring an additional 28,251 shares during the last quarter. American Century Companies Inc. boosted its position in Health Catalyst by 1.8% during the 4th quarter. American Century Companies Inc. now owns 710,481 shares of the company’s stock valued at $5,023,000 after purchasing an additional 12,682 shares during the period. Finally, Martin & Co. Inc. TN boosted its position in shares of Health Catalyst by 80.0% during the fourth quarter. Martin & Co. Inc. TN now owns 490,998 shares of the company’s stock worth $3,471,000 after buying an additional 218,293 shares during the period. 85.00% of the stock is currently owned by hedge funds and other institutional investors.

Health Catalyst Stock Performance

NASDAQ:HCAT opened at $4.02 on Thursday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41. The stock has a market capitalization of $282.25 million, a P/E ratio of -2.98 and a beta of 1.43. The company has a 50 day moving average price of $4.72 and a 200 day moving average price of $6.57. Health Catalyst, Inc. has a fifty-two week low of $3.60 and a fifty-two week high of $9.24.

Wall Street Analyst Weigh In

HCAT has been the subject of a number of analyst reports. KeyCorp raised shares of Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 price objective for the company in a research note on Wednesday, January 8th. Wells Fargo & Company dropped their price objective on shares of Health Catalyst from $13.00 to $10.00 and set an “overweight” rating for the company in a research note on Tuesday, January 21st. Evercore ISI cut shares of Health Catalyst from an “outperform” rating to an “inline” rating in a research report on Wednesday. Stifel Nicolaus lowered their target price on Health Catalyst from $10.00 to $5.00 and set a “hold” rating for the company in a research note on Thursday, February 27th. Finally, Stephens decreased their price target on Health Catalyst from $7.00 to $5.00 and set an “equal weight” rating on the stock in a report on Thursday, March 6th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, Health Catalyst has a consensus rating of “Moderate Buy” and a consensus target price of $8.73.

Insider Transactions at Health Catalyst

In related news, COO Daniel Lesueur sold 16,902 shares of the firm’s stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $4.52, for a total value of $76,397.04. Following the completion of the transaction, the chief operating officer now owns 216,250 shares of the company’s stock, valued at approximately $977,450. This trade represents a 7.25 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, General Counsel Benjamin Landry sold 13,827 shares of the stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $4.55, for a total value of $62,912.85. Following the completion of the transaction, the general counsel now owns 160,437 shares in the company, valued at $729,988.35. This represents a 7.93 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 54,030 shares of company stock worth $263,269 over the last ninety days. 2.50% of the stock is currently owned by corporate insiders.

Health Catalyst Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.